Vol. 6 (10) pp. 976-982 DOI: 10.21474/IJAR01/7895

VIRAL LOAD AND T CELL SUBGROUP DYNAMICS OF PATIENTS TREATED FOR CHRONIC VIRAL HEPATITIS B.

, and
  • Department of Internal Medicine, BEU, Turkey.
9 Downloads 55 Views
Crossref

Download Full Paper (PDF)

Abstract

Backround: T cell activation plays an important role in tissue injury and viral clearance during the antiviral immune response. In our study we aimed to assess the viral load and peripheral blood T lymphocyte subgroup dynamics in the first 6 months of treatment for patients with chronic viral hepatitis B. Material and Method: A total of 31 naive patients without previous treatment were included in the study. For at least 6 months, 16 patients were given 300 mg/day telbivudine and 15 patients were given 100 mg/day lamivudine. Laboratory values were determined at the start of treatment and in the 1st and 6th months. Serum HBV DNA load was measured with PCR and peripheral lymphocytes subsets were measured with flow cytometry. During the treatment period, multistage analysis of the reduction in HBV DNA levels and peripheral blood lymphocyte dynamics was performed. Results: The HBV DNA values in both groups fell to non-measurable levels in the 1st and 6th months. In both groups the CD4/CD8 ratio was similar and there was no significant difference in CD4/CD8 ratios during follow-up (p>0.05). The increase in CD8+CD28+ and CD8+CD38+ T cell levels was inverse to the reduction in viral load and the increase in both groups in the 1st month was noteworthy. However, though viral load continued at levels that could not be measured, the clear increase in CD8+CD28+ and CD8+CD38+ levels in the first month ended and formed a plateau leading to the consideration that this may be associated with viral load. Conclusion: We believe focusing on immune mechanisms will increase the treatment success of new treatment modalities for chronic viral hepatitis B treatment.

Keywords

Article Analytics

References

  1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. International journal of cancer. 1999;80(6):827-41.
  2. Maini MK, Boni C, Ogg GS, King AS, Reignat S, Lee CK, et al. Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection. Gastroenterology. 1999;117(6):1386-96.
  3. Baumert TF, Thimme R, von Weizs?cker F. Pathogenesis of hepatitis B virus infection. World journal of gastroenterology: WJG. 2007;13(1):82.
  4. Wu J-C, Chen T-Z, Huang Y-S, Yen F-S, Ting L-T, Sheng W-Y, et al. Natural history of hepatitis D viral superinfection: significance of viremia detected by polymerase chain reaction. Gastroenterology. 1995;108(3):796-802.
  5. Boni C, Laccabue D, Lampertico P, Giuberti T, Vigan? M, Schivazappa S, et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos (t) ide analogues. Gastroenterology. 2012;143(4):963-73. e9.
  6. Lau GK, Cooksley H, Ribeiro RM, Powers KA, Shudo E, Bowden S, et al. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B. Antiviral therapy. 2007;12(5):705.
  7. Strioga M, Pasukoniene V, Characiejus D. CD8+ CD28− and CD8+ CD57+ T cells and their role in health and disease. Immunology. 2011;134(1):17-32.
  8. Bocko D, Kosmaczewska A, Ciszak L, Teodorowska R, Frydecka I. CD28 costimulatory molecule--expression, structure and function. ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS-ENGLISH EDITION-. 2002;50(3):169-78.
  9. Tan A, Koh S, Bertoletti A. Immune response in hepatitis B virus infection. Cold Spring Harbor perspectives in medicine. 2015:a021428.
  10. Huang C-F, Lin S-S, Ho Y-C, Chen F-L, Yang C-C. The immune response induced by hepatitis B virus principal antigens. Cell MolImmunol. 2006;3(2):97-106.
  11. Yuen M-F, Chen D-S, Dusheiko GM, Janssen HL, Lau DT, Locarnini SA, et al. Hepatitis B virus infection. Nature Reviews Disease Primers. 2018;4:18035.
  12. Liver EAFTSOT. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. Journal of hepatology. 2012;57(1):167-85.
  13. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661-2.
  14. Liaw Y-F, Kao J-H, Piratvisuth T, Chan HLY, Chien R-N, Liu C-J, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatology international. 2012;6(3):531-61.
  15. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. Journal of hepatology. 1995;22(6):696-9.
  16. Savarino A, Bottarel F, Malavasi F, Dianzani U. Role of CD38 in HIV-1 infection: an epiphenomenon of T-cell activation or an active player in virus/host interactions? Aids. 2000;14(9):1079-89.
  17. Bofill M, Borthwick NJ. CD38 in health and disease. Human CD38 and Related Molecules. 75: Karger Publishers; 2000. p. 218-34.
  18. Cao W, Qiu Z-F, Li T-S. Parallel decline of CD8+ CD38+ lymphocytes and viremia in treated hepatitis B patients. World Journal of Gastroenterology: WJG. 2011;17(17):2191.
  19. Tilling R, Kinloch S, Goh L-E, Cooper D, Perrin L, Lampe F, et al. Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. Aids. 2002;16(4):589-96.
  20. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. Journal of Experimental Medicine. 2000;191(9):1499-512.
  21. Li X, Kong H, Tian L, Zhu Q, Wang Y, Dong Y, et al. Changes of Costimulatory Molecule CD28 on Circulating CD8. BioMed research international. 2014;2014.
  22. Cao J, Zhang L, Huang S, Chen P, Zou L, Chen H, et al. Aberrant production of soluble co-stimulatory molecules CTLA-4 and CD28 in patients with chronic hepatitis B. Microbial pathogenesis. 2011;51(4):262-7.
  23. Thomas HC, Brown D, Routhier G, Janossy G, Kung PC, Goldstein G, et al. Inducer and suppressor T‐cells in hepatitis B virus‐induced liver disease. Hepatology. 1982;2(2):202S-4S.
  24. Carella G, Chatenoud L, Degos F, Bach M-A. Regulatory T cell-subset imbalance in chronic active hepatitis. Journal of clinical immunology. 1982;2(2):93-100.
  25. Alexander G, Mondelli M, Naumov N, Nouriaria K, Vergani D, Lowe D, et al. Functional characterization of peripheral blood lymphocytes in chronic HBsAg carriers. Clinical and experimental immunology. 1986;63(3):498.
  26. Robayes G, De Groote J, Vandeputte M. Suppressor cell function in liver disease. Lancet. 1983;2:342.
  27. Regenstein FG, Roodman ST, Perrillo RP. Immunoregulatory T cell subsets in chronic hepatitis B virus infection: the influence of homosexuality. Hepatology. 1983;3(6):951-4.

How to Cite This Article

OnurOzdemir, MuammerBilici and SevilUygunIlikhan. (2018); VIRAL LOAD AND T CELL SUBGROUP DYNAMICS OF PATIENTS TREATED FOR CHRONIC VIRAL HEPATITIS B., Int. J. of Adv. Res., 6 (10), 976-982, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/7895

Corresponding Author

Muammer Bilici
Department of Internal Medicine, Bulent Ecevit University School of Medicine, Turkey
Creative Commons Attribution 4.0 This work is licensed under a Creative Commons Attribution 4.0 International License.